Rockwell Medical (RMTI) 9 Nov 202020 Q2 Earnings call transcript

[00:00:03] Good afternoon, ladies and gentlemen, and welcome to the Rockwell Medical 2020 Q3 results call as a reminder this conference call is being recorded at this time. I'd like to introduce Claudia Styslinger Investor Relations. Please go ahead.

[00:01:34] Welcome to Rockwell Medicals third quarter Twenty Stys linger earnings results call, this is Claudia Stifling of Aagot Partners, the investor relations representative for Rockwell Medical.

Joining me from Rockwell Medical. Dr. are call today's On Russell Ellison, vice Officer Russell executive Dr. executive Cole, and chief financial chief and president, marketing, Business president officer officer vice Shipstead, of president and Tim Chief officer, Hoffman, who Mark medical will joining Q&A. us be for chief

any based believe. continue such plan should, to predict, upon I medical current expressions platform. Tritak statements May, will as or are but looking Words project that belief similar expectations certain the Rockwells pirogues Expect, not products phosphate laws, intention forward or might, will, including, intent, meaning statements. dialyze statements of and forecast, future limited Before could discuss wanted matters I tind or and constitute estimate, Brockwell regarding may to anticipate, we commercialize potential Avenue looking note begin, securities to forward within we the federal

future these available forward SEC those are be statements Rockwell upon looking forth are to risks and information not undue actual results on limitation, can to Medical's accessed conference different. alter on any conference result over placed like you on as expressly time, current in materially Medical's by November While that to except obligation statements. turn four Accordingly, the various expert chief executive our These page. on update same which inherent also and rebroadcast This Web and this disclaims including can of are uncertainty. events based Russell Investor or any reliance which be recorded audio call Allison subject be statements to release, undue forward should not call as being without otherwise, which such on this forward believes a I place Rockwool looking twenty subject Twenty page. estimates forward subject looking This uncertainties, would are of rebroadcast, required the officer, to date to change the reliance these based should on assumptions Rockwool of whether Dr are Xth. or looking filings, law. Medical accessed Medical's Web any on Relations beyond Brockwell new and many information, set statements medical control could is statements, call us be to At Rockwool are Russell. reasonable,

and pertinent approved Claudia.Good everyone, your on review activities next afternoon, analysts implications of commercialization outcomes [XX:XX:XX] the from covering other steps the potential received value our we'll around international to time. second we thank of Call, for build anemia the to update Tricor the our launch corporate upcoming progress on you, our our some for treatment transforming continued to for our iron for today's Rockwell world first company would for the deficiency Thank answer Medical by vision is and on Today EPS platform email. improve say of focused Avenue, patients. you of FDA partners And for an questions each of we and financials. we'll our and preparations will updates then and address and on FDA our a product, strategy product, approved take our new the questions I

hormone deficiency are intravenous people afflicts regulated treatment to effects. iron the and to because is by iron absorption have iron cells from in and And options And the cardiac nutritionally two including establish iron and to and absorption side deficiency dizziness elemental can iron iron is Our and million deficiency Iron experience suffering people billion tightly is due function. of side have who orally million with by challenging anemia. vision availability of fatigue, patients States anemia manage Patients worldwide iron to alone, and effectively toxic the situations. a reduced iron approximately Current are required iron is subset deficient, who poor five standard care anemia deficiency many often for new iron XX is limitations have suffering the deficiency body, United deficiency anemia. extreme in deficient.

side current into makes iron which ore cells. as forms the This transport situations and dialysis. to releases then available iron iron in However, to the transferring slowly IV release blood be PE's such reduced of can and which the substantially cells iron release white liver, by inflammatory protein

transparent, to SPC companies tissue inflammation phosphate platform. has value immediately that platform Our EPS unlock directly transport to to the potentially protein and iron hire or is of the attributes, of the immediately technology citrate, available iron and this transformative releases independent

congestive animals are deficiency believe cardiac over years. team We development, focused function. strategy, that as clinics, improve our heart to unmet company on be put that we management that relevant developing that potentially and strongly patients we We and hemodialysis iron and drug other with build medical biopharma the believe for public to Where sales have experience will hemodialysis, the now with trials the in receiving track dialysis infusions marketing their ION has manage we a needs. clinical next to treat commercial and anemia, on significant anticipate several company way F.C.C. value a can management. such medical for with hospitalized failure and transforming patients We patients home important, conditions

We presence XX for excellent reliability where an have business across a solid country have service. and clinics million that and the dollars in gives dialysis reputation we a core us over annually generates

one launched. about We have market branded right one in be the the product and there to second

we We growth have to expect over time. partnerships generate significant that international

full but sufficient I'm uses SmallCap recent trials, as generate delighted which in we Family extensive And you value public and occur our actually biopharma financing, clinical efforts company to enhancing partnering, [XX:XX:XX] us and Shipstead potentially interactions, development also creation grow in the the in raise, has Russell will sector launched. new to thanks are that now Rockwell for in achieving joining, that his sales. are new will sales readouts significant the the have enrollment new and September Companies Attaining us welcome us all developed of goals. and pipeline not for familiar CFO we meet EPS a with from completing joined future, as these milestones, expect in from only experience milestones already are of being before they multiple Those provide to our officer.Russell our capitalized management drug drive can trials. the the chief we before M&A. to uses value Biotin help well of With well on with have company. such resources are FDA position capital come understand that business his We well to biopharma and certain commencing data value of

expanding twenty Now, to early Alesi our Trocaire into IV be home TRIPEROXIDE launch for for we dialysis one. launched, developing of reach the the our in and to FCTC future, States, the global and strategically of next of first across year our concurrent twenty infusion the with soon and indications, key trifecta, new to sales commercial and U.S. United three maximizing the quarter Avenue, Tripura Tripura platform In tracks, partners the program. sales formulations Califate to beginning prepared centers continue nationally of are build momentum

China, and Our Korea Latin America. global efforts fronts are many India, progressing on

important development term, there new value creation, For outside believe is the indications through and the for hemodialysis EPS for both potential we of near setting, long of the where indications, platform medical needs and managed we and to experiences significant will clinical two approved. way are iron of where there deficiency to transform leverage deficiency FDA the iron and the anemia is date

with risk an is pursue iron EPS can of top tolerated due met inflammatory iron often with conditions deficiency undergoing well not indication because by therapy. home or which for office or be suboptimal iron the Our the iron new an infusion, these requirements is products. infusion to the in visit to which oral patients anemia is priority, supplement, I.V. requires treatment Currently, only either of hypersensitivity

million FDA through a clinical by or and available twenty estimated Benefit. market could the However, as by or standards in be twenty type meeting one. quarter, and these therapy therapy patients through hospital rapidly incidence to we to two hold already home. savings two costly hospitalization reduce part to infusion in Medicare of administered because percent area pandemic. one. is three Home largely XX line of point discussion patients large and driven the care, phase to that this every intend Medicare Home served cost B. development based office subset with of quarter covered will could the growth of the is at Twenty landscape currently favorable, patients be payers treated The nutrients. a next and We improving of infusion. estimate emerging medicine, home The half to Pending for is want studies FTC resulting EPS second payers our submit continue, the high twenty home commence With approximately available as a likely XX global be of office infusion anemia administration of growing versus currently a of C trend IV we under with and coverage that first over [XX:XX:XX] year percent. from estimate deficiency to commercial drugs believe reimbursement visits the safely We plan iron Infusion access specific for in

as uptake a than the FESSEY in patients for patient of are to bioavailability, with if congestive with therapeutic failure. growing relative use hospitalized may million clinical heart with is clinical heart are support able the be each consideration under some such a population, of because opportunity patient benefit EPS IONSYS, evidence which decompensated are replacement to we second in current ihram in IVR significant unmet limited body inflamed failure, needs failure. of More an population therapy. this exists patients year heart feel particularly The that patients and and as The address options

expected can of in sales acute hospital providing creation ReliOn track of you to forward to approach indication. a However, as and includes older forms partners to strategically twenty three U.S. to QX the developing dialyze snapshot product be benefits indications milestones with pathway our setting. failure two current these our FDA failure global commercial regarding for consistently America value you Avenue, of U.S. with following a the regarding [XX:XX:XX] Tricare FDA and consultation expanding clinical and is a updates and liver heart this parental twenty of slide patients the benefit our consultation launch, likely throughout infusion months in These too for from and see, of future meaningful EPS and as regulatory on home four this provides the EPS release reach one and We beyond. America. key commercial and platform heart as of approvals products, demonstrated focused clinical and have in product development slow the U.S. Now, include multiple health setting. clinical milestones, throughout for new numerous outpatient Latin starting North upcoming look milestones new FTC active the with Asia, development But well produce with milestones of iron to studies launches product for twenty

customers We growth Regrettably, million our is is than XX facilitates dependent concentrates key US are allows that including downstream the three of customers. in And receive us revenue both have around current continue pharmaceutical multiple on the two patients concentrated our XX and a to in relationships we nearly with and week. multiple customers. number stress one and failure, and many States. the continues countries baby from products Tripura covid-XX supply the In going clearly impact already for a kidney we more the life times develop literally reliably lives we quite and harvest each industry [XX:XX:XX] carrying the prospective concentrate year, this pandemic forward. business are acute discussions business through further industry of within unique in put the and profit impacts United yet clinics. to saving which be The treatment the challenge dialysis and failure. treatments with the is organ dialysis patients pandemic annual million Well, and supplier are they outpatient driver on to our business and of faces addition, the per from not can covid-XX states to world The because comorbidities generate

is role I pleased that. patients and am to in absolutely care health critical, Our providers share and supporting

for challenges chain testament see We is childbearing. our no hardworking or to continue to disruption This our supply pandemic. to employees posed adapted the who either to concentrates by a the

medical our access have restricted significant clinics mentioned workers, This promotion caused has the virtually in tri As this our focus we of sales continue and by have on the we ability ferric calls where working they including to prior non-essential have have continue efforts representatives and for in to managing year, to clinical that to and educators, change impacted any our earnings been protocols crisis. possible. facilities educations dialysis nurse

is With continue will the states, many resurgence reopened. unclear that the have and of for states how it these covid-XX restrictions in long

resume necessary precautions. have taken safety to clinic We measured visits, steps taking in-person

are impact the covid-XX to discuss and the partners launch global over potential to new We commercialization. partners metrics evaluate these the of now in contact Tim. close clinical our commercial I'll and on timelines with to call hand for development Tim Cole of plans.

the of continue Russell. the despite tri Thank [XX:XX:XX] the third make we commercialization In the dialyze, challenges quarter, you, pandemic. in of to progress covid-XX important

compared treatment four the translates annualized of approximately of hundred, thirty increased quarter. have we quarter, restrictions our was five than patients increase third approximately from hundred due the in-person in of end to the to an lower on number growth clinics which to contracted overall dialysis expected, volume The sales to last visits of thousand As primarily Christchurch field levied meaningful staff. the

we clinical on with educator which us quarter, clinics and by nurse continue to contracts. sales However, training programs the and allowed tactics in-person leveraging to to track results complete restrictions, close reengage training relax produced engagement are have the more geographies back virtual planned with that programs. pleased In US and get certain has are teams

world fall, data cases continuing experience adapt and hand quarter. we increase new year, of the We instituted on have needed. the from real are happening first the as and monitor With in to first a launch, in will the number we this covid-XX third initiatives

we're when process and First, move encouraging clinics the bypass contracts evaluation purchase possible. to to straight

Second, adopted have we strategy. aggressive more a pricing

some educational management to programs cycle While place covid-XX, of of has us sales and for increase to the [XX:XX:XX] these introduced the jumpstart new allowed much overall dialysis. a have recent they in Third, awareness its by been broader in combined efforts and cases. in we slowed have and implementation are needed shorten traffic traffic in promotional

disease touch, dialysis tool have New clinical nephrologists program and kept a series. programs Fourth, presence try a promotional at scientific education we've fresh start include for speakers analysis non campaign our nurses branded for a And kit. a both awareness level our as a abstracts that recently presence media Congresses, Society concluded exhibit and Booth, including scientific three increased the have where symposium sponsored American This virtual adoption of best on on we triffid a submitted Congress, is Last, important value the Nephrology we scientific to the posted social leads highlight accepted posters. we Rockwells were that activities and and dedication to programs which product. the moves for dialysis we these of culmination will as drive of expect real of Tricor. pandemic see the global us resolution, long acceleration results. adoption personnel, towards community. sales execution high groundbreaking hands our a to the importantly approach Once believe is process That's the support, field by term of high yield's specifically our

access Avenue, try IV the our intravenous allows option. options portfolio I'll thus is our expanding a in dialysis Twyford. is kidney greater regardless is Technology is FDA [XX:XX:XX] dialysis which for the preferred to using Tricare dialysis of maintain in dried our with being hemodialysis product iron turn to replace patients more cases administration approved providing by as Park mode and traffic of patients And it's Trackwork and of So platform where chronic administer clinics. of enhances indicated dependent for to not administration used. is Avenue line an delivery to formulation products The only appropriate designed traffic Avenue hemodialysis and bicarbonate bicarbonate. extension the adjoins with therapy the and patients Tricare to Third by centers adult disease. hemoglobin next, Tricare clinic

out in this due the increase We're to have to the pave to the with order to includes twenty customers have of been Fryeburg commercial fair Currently, Now, started the powder in our outreach adopt about unable adding trade ongoing. who by current in in reaching expressed customers to adoption existing technology. is launch of commercially in product but also the to dry it agreements past, to for dry once interest quarter discussions available. Got customers upcoming twenty of is current Academy prospective and already Abney second awareness use their way treasurer of

our to Originally, We promoting at the the annual in are at have for Exhibiter started try an virtual commercial QX we of will production signal to Avenue of the product introduction had program planned year. initiated part clinics integrated the traffic of Spotlight provide and as the marketing, ascend communications recent delay of been our we evaluation cost programs salable timeline for finalizing exhibit First now the of in next while availability programs fourth a Congress educational generate Avenue excitement booth. samples quarter no These Traffic the our the in Avenue in and product. and release program scheduling that market We Triffid in included parallel, evaluation this expected of to In October. year, to has the packaging early for at programs but the trial commercial due to extended avenue first minor of product. report

to have will customers and program, shown to. selected benefit the we comprehensive While try results, feel report interest in patients if too from it's that early treatment, they

of Our to twenty of in twenty field and introduction also Tritak help and in when updates traffic commercialization of medication one. educators evaluate regarding first support product an experience commercial We salable Trife nurse to provide Avenue, we'll for efforts our Avenue quarter to the forward schedule reports. look of ensuring marketplace important and of believe continuing future the education regular programs the available field proper use for is reviews while these evaluation training them We impact lab team the staff.

that In believe reimbursement, Avenue terms competitive patients. structure gross bundle dialysis enables been SRT that cost importantly, and for clinical to while Trifunovic within Trifunovic clinics. will the the Avenue price be we us reimbursed of make attractive Medicare [XX:XX:XX] value But ensuring an margin has and is to the payment product established for provides financial

Now, expected alongside an anemia position introduction class eyes, to like treatment traffic anemia to patients. entirely of plan reliable skies management and physiologic are agents his a to upon We to would which the and new the anemia hemodialysis. management of of hemodialysis touch anticipated to in the change lastly, of strategically I provide

in the of that the The range patients start, achieved related managed a well further providing our updates coming patients to come with expect of twenty source agents, Phase an one. to iron was We the on given to requirement of dialysis in within for the expected in introduction twenty mean with to presented forward Rocksteady set prostitutes the look We important Trifunovic him can early that. year's dialysis Trifunovic, months. that that at first which the requirement this could with is iron the be three session, each Rocksteady market the be is Present in trackwork in such assent. strategy opportunity sufficient trials

So Russell. I'll Tritak to updates international with financial over turn results. call the QX our to discuss Russell Shipstead that, and

attractive rate in making partner, been issues Thanks, years, increase to China. been commercialize hemodialysis a into have with the is Sun quarter hundred over We for Indian to India exclusive great is in the earlier, Dr. jailed market in regulatory one to from the Standard with [XX:XX:XX] with over in also to Control continuing in hemodialysis is once announce for patients. has and rights China the for with hemodialysis the Sun Ellison world. logistical Committee. entered in the the rapid shipping single Pharma XXXXXX pivotal as Central launch Trifunovic Biopharmaceutical, the an in Organizations market, at commercialize patients agreement entered a has partnership study stint, recent in in to access get we India. Korea. enrolled thousand Trifunovic twenty year, Wang working progress been with this South rights our approval soon into It an pharmaceutical patient Earlier largest Technical Drugs resolved, hope to some China. first mentioned the third company is We Bong license

begin market ideal commercialization not represents two. anticipate patients thousand it believe Jail activities. Korea trial with regulatory twenty responsible a seventy an in approval, that be so eight will is twenty opportunity, hemodialysis partner. They over advised sizable growing a in that South We we require annually. will jail us for and early to and advance clinical receiving of all sales

is this to approval course, in Of Korea. regulatory subject

potential and also Latin We progress Europe Japan, markets in key with are America. other making discussions partners in like

during used about equivalents having months point close dollars. million, period a in quarter twenty markets fourteen twenty September activities was fifteen growth the of This cash potentially to approximately loss the to sales gross raise nineteen. dollars, comparable thousand. This of last without were revenues during cost the which and approximately two results, quarter Now, for anticipation to to launched cash, of twenty hundred turning in sales is was for hundred to net of million the quarter the foresight of was three the year. XXth, third Net sales and increased nine cash the the million capital approximately dollars. capital resulting during the same a us year. Twenty of the than with elections execute million, four Trifunovic four But point Cost which allows position were capital and September with sales in the three ended covid-XX one last and we gross quarter fifty volatile Cash strong our profit since ended quarter strategy the dollars nominal in to nine third there only second XXth twenty a of volatility the third September. of were third fifteen year. point raise on is comparable of period ended sixty a economy to million last quarter quarter twenty Twenty worrying Traceroute [XX:XX:XX] operating third raise nominal uncertainty seven for third thousand We for more eighty same compared to the to continue three approximately the our ended and liquidity market. with due quarter in nineteen, and in months investments

partially prior point the net dollars primarily operating in in third increase Russell quarter of year Ellison expense. a nine twenty third Finally, The driven compared was million by million improved last point which was four dollars improvement seven in closing seven loss spending, for to reductions from loss twenty for remarks. and approximately offset by quarter Gené to will commercial year. in of to I now an the call both R&D back spending and interest the his turn the

avenue EPS new indications commercial despite China. covid-XX expected launch the pandemic are when the we resolve. patients developing for third early adoption expanding and for soon Thanks, U.S., to global our a company reach beginning into now with in We've sales the our be in next of across we three significant our of we traffic Avenue, and drive US continue to quarter many commercial in value future, year partners [XX:XX:XX] key making dialyze launched, to concurrent the final creation we made Trifunovic infusion begins to fronts, across adoption continue of tracks, to the expect headwinds, therapy Triphammer maximizing platform, acceleration Russell. and to progress and of Triboro covid-XX strategically and drive for the soon see requiring with And preparations home

pivotal three is Our the trial of its and Triphammer about partner, in Phase first enroll patient to Windang India. Pharmaceuticals,

all submitted partners documents for Our for marketing. process its and regulatory approval appeal pharma

the like to exclusive pharma And South third Some clinical a marketing. as indication QX with in FDA Korea, EPS pharmaceutical and to one. a We're twenty next commercialize to is covid-XX. home platform twenty quarter navigating to expected in our our quarter priority, of progressing that clinical execution is financial steps that, twenty new value to into We be jailed temporary the position license we questions development of mission by we a infusion with expected now in parallel country's plan company received trial our required three not that type the steaminess regulatory entered rights we the some strategies for for ended twenty creation. in for due QX the the a of in strong to review prior where to an enable [XX:XX:XX] Ferrick country, suspension address With our to in email. due agreement expected

The whether believe reflects regarding stock price questions company. the of were the it of first performance set and value we the

out. Now, Tricare multiple partners driven I programs soon to will indications Avenue, can't really we milestones. new and strategically our build commercial We're the for that do developing of laid value we're value. price, I have US as And dialyze and to potentially Trife talk our confident most talk launched key to we across about build have as about the maximizing driving, creation these but reach And value platform. tracks, strategy value EPS can move concurrent said, through milestones we three sales that stock Trife expanding be commercial, global

I we Another face think this in quarter but you set of of Tim the mean, have Tim, are dialyze progress perhaps, Trife, the this. pandemic. Eric headwinds from on performance comments of addressed questions addressed the already, and has I making the covid-XX and more

Russell. thanks, Yeah, [XX:XX:XX]

expect quarter also reiterate, to for dialysis expected, QX resistant covid Just they being in us continue restrictions we where reengage these to making to engagement progress. to mentioned, of and in But the it we that an three, have see tactics, have need embrace have helping relax that as And sales us and And that towards time. many certainly due but starts more with the this primarily process. than during which to was definitely to protocol to do we growth us Christchurch along pleased cases an purchase in making aggressive world time, visits, in-person move pricing do not only we contracts overall trajectory on some to for is move and to resolution, But the cycle encourage hand geography's wants courses, and clinics, to And indeed see field allowed at been our allows implemented strategy, changes sales not I and virtual with was we straight Twyford a relaxed evaluation is from as the covid data tactics restricting restrictions uncertainty. we restrictions traffic improve. real lower that clinics cases. and of shortened

Jim. Thanks, [XX:XX:XX]

Now the turn questions. over the line operator for to

if please, and move to Ladies some like then [XX:XX:XX] cell question, star, phone. on the cell you'd a gentlemen, your one phone touch, ask to press

question. Again, star You the pound to ask one press that's key. the

one first question Joel, Brandon, is Our comes open. from Kansas No folks as of

en and Can that? in to type color additional hear one seen when required we Any or the And past. one you? infusion are for commercial factors to an C be before temporary you Sorry, could quarter expect talk [XX:XX:XX] able any in have Thank through impact get still twenty to the any we've launch That launch? lot nothing you gating needed but the additional provide the you on you. meeting. on of may to then about this. to margin a in one. to of lastly, timing home route any that to than Can better are provide color gross Just launch terms a seemed

Tim, so Ok, maybe. [XX:XX:XX]

question me meeting let that's C want You Brandon, straightforward. sorry, take to. type pretty the

be expect those address February, to in. That questions? Tim, do want one The late would this early of March. We probably estimate. our you another

mentioned, that to, delivery with the scheduling Certainly, on barriers minor Europe. do was we no so first expectation [XX:XX:XX] in of of the the always anticipate basis, with speak for was I any there delays, And delay to comfortable that issues. saw our And production commercial as we the the but packaging further moment, further the other, we're would to are quarter. in could be there supplier of I I say, manufacturing not Avenue can related production. launch,

[XX:XX:XX] is. had I Ok, other which think Brandon, one question, you

[XX:XX:XX] Yes, I'm lot margin, last at it, just experienced seems be this than we of the to on a the higher beginning looking just year. at year gross it

product any just So is mix or terms from. in of color it that

Russell, do have [XX:XX:XX] on This is any mostly product mix, that? comments you but further

and thing I would to cost one you is more the we effective. make are say Well, [XX:XX:XX] processes know, that, our efficient trying

to that seen one we be gross have being but think going as can going costs take the try we're a out excess possible well forward here. But early so net as it's I the but So taking of of also margin it. as only have that hopefully focuses not is is to hopefully to margin, stages we're efficient of

So tuned very for going that that. process right is a That heavily going we're stay now. at very,

[XX:XX:XX] Ok, much. thank you very

of [XX:XX:XX] Iran Wainwright, Armstrong question doping. from Lance H.C. Our next comes

pivotal [XX:XX:XX] how few real Trifunovic a development. sense to us in with international give one trial you Just the given enrollment expects take on in Can China, of if to haven't guidance to it full reach questions any they the start that long or timeline? you a regarding

Mark, [XX:XX:XX] get when we'll about sure. we some talk Sure, more. this

you Thank question. the for [XX:XX:XX]

the we on anticipating And of enrollment, early start Russell, of sometime have from of subscribed a heard speed the depending were you we first as half should three. twenty So study fully study year. next sometime twenty in a the

are of looking or the what and then to they Ok, persist Indian [XX:XX:XX] indefinitely? of any regard suspension regulators when India.Do to regulatory to sense rescind have to you would with the for review likely that's with due covid-XX respect in situation the

to haven't question haven't guidance I any got incidence much but know, we seem about That's for very good wish be certainly and don't incidence I really that, bad. rate which firm the [XX:XX:XX] And in cases, is, of to rate had of sort what with. very was a related India really you answer a I I

that allow thing. know, sort meetings happen You regulatory to and of

we know. So don't really

to it's news out. but So is know is we time, Don't going short long be a a that to very time it's don't be going the we. the good that news bad know

from just they really connected get authorities. sure soon India, which in that with major to And open the I'm hear company should is we're as pretty the meeting. Pharma, up, very waiting So in able as we open Sun a start is authorities be or to a up to

programs with then Ok, of World on of if very just can dialysis. kind those Program of programs with to close following provide regarding the any evaluation metrics you [XX:XX:XX] comment status effectively you evaluation the the when the updated with secondly, then quickly and Trifunovic the Data Avenue And what you and product? aid, can us expect rollout the formal on Real

the I'll the Take [XX:XX:XX] first Tim, answer two last and questions you second, one. want the to.

absolutely. Yeah, [XX:XX:XX]

question. So thanks for the

programs first started early October. in evaluation Our only

how really to us mentioned adopt. report evaluations what negotiation which as the going on evaluation of I awareness program October our to is to target customers So the well of clinics through our for is I explained occurred this our early But eligible as for various an versus and of done we vary about program are product. clinics The program. with comprehensively it's how to it's based American now, cost many to too go the in of in heavy Society on Nephrology channels have earlier, going promotion among segments, increase Congress, length length which in

cycle But results to there. trying evaluation first from But to program commercial we're certainly apply the our launch we the say early the there. quarter. to sales learnings first in are accelerate will but So what the

States current We've world And do [XX:XX:XX] as get set, contracted the to data a the been. that to is an which data set a it. good on provided we've restack, question data is renal in-depth takes firm received and the one. United real dove while by very We recently disease service

we'll multiple tenure so using evaluating XX month product. of a to about month And with nine the be clinics

data pretty device set should we as there and and is a and outcomes is also as inputs. in and as so have well hospitalizations the and includes information drug such comprehensive So on, data deaths that dialysis,

first hope set, quarter in in first would year, the a that the now, So data hope. I be earlier next we're we have should it that Certainly we analyzing as than quarter very that. nice would

Great, very [XX:XX:XX] thank much. you

back answer marks. concludes Malpaso, This [XX:XX:XX] question on Russell, call to session and also question our

us the on taking for this forward in you coming up be with to times you So in of time and for this [XX:XX:XX] all afternoon call, and these to many thank the we look joining following weeks. interesting days

So gentlemen. much, and thanks ladies very

[XX:XX:XX] This conference. does conclude the

disconnect Have great day. a You may everyone. now